BASIC// DISCOVERY

PURSUING the POTENTIAL
for RNA BIOLOGY

RNA IS ESSENTIAL FOR THE PROCESS OF TURNING GENES' DNA
instructions into the proteins that actually drive
cellular functions. The field of RNA biology is
dynamic and growing, as researchers discover
the functions of a dizzying array of types of RNA.
Jefferson’s RNA biology program is multifaceted
and rich with potential for both understanding
human biology and developing ways to treat or
prevent disease.
For example, Ya-Ming Hou, PhD, professor of
biochemistry, guides a basic science research
program addressing RNA’s roles in a range of
biomedical challenges, from cancer to antibiotic
resistance. Recently, she may have identified an
RNA-based vulnerability in gram-negative bacteria
such as E.coli and Salmonella—which are antibioticresistant because their cells have two membranes
and numerous toxin pumps that expel antibiotic
molecules. Dr. Hou’s group has shown that creating
a defect in a specific transfer RNA (tRNA) undermines
those defenses. This finding holds promise as a
path for pursuing new, more effective antibiotics.
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tRNA molecules are not a typical antibiotic target;
they are part of the protein-building machinery cells
need to function. But Dr. Hou’s team found that to
function properly, bacteria require the addition of a
methyl group to one particular location on the spine
of several tRNAs. When these tRNAs were deficient
in methylation, the cells were more likely to have
protein-building defects. Next, Hou’s team created
bacteria genetically deficient in tRNA methylation,
and showed that the bacteria had more-permeable
membranes and were less effective at pumping out
chemicals, compared to normal bacteria. Finally,
when the bacteria with defective tRNAs were
exposed to antibiotics, they died faster and were less
capable of developing drug resistance. The team is
now screening molecules that could drive the same
de-methylation effect as the genetic engineering;
and, because the target in bacterial tRNAs is absent
from human cells, the resulting drug could be less
likely to have off-target effect on human cells.
Dr. Hou and colleague Davide Trotti, PhD, professor
of neuroscience, have also been studying the role
of specific tRNAs in neurodegenerative diseases
such as amyotrophic lateral sclerosis (ALS)—pursuing
investigations of a particular tRNA’s role in the
disease and whether it could be a therapeutic target.
In that context, Drs. Trotti and Hou have undertaken
an NIH-funded study on the most common cause
of inherited ALS: a mutation resulting in patients
having hundreds or even thousands copies of
GGGGCC sequence in the gene C9orf72.
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Recent work by Dr. Trotti’s group—in collaboration
with Aaron Haeusler, PhD, assistant professor of
neuroscience, and Piera Pasinelli, PhD, Frances
and Joseph Weinberg Professor of Neuroscience
and Director of the Jefferson Weinberg ALS
Center—looked at what triggers these repeated
sequences in the C9orf72 gene to eventually
produce the toxic proteins associated with ALS
(as well as with frontotemporal dementia and
other neurodegenerative diseases in patients
carrying the mutation). Suspecting that stressors
may be a trigger, the investigators tested a
number of agents that cause neurons to turn
on the stress responses. Indeed, many of these
also initiated production of toxic protein. The
investigations also showed that neuronal over-

excitation—similar to what happens during a
seizure—also triggered the protein production.
Once the integrated stress response is activated,
it is difficult to stop the production of the toxic
proteins. But, by honing in on this over-arching
cellular mechanism, the researchers gained insights
on specific methods that might block the neurondamaging response. The drug trazodone, which is
approved for the treatment of depression, is known
to act on parts of the integrated stress response.
The researchers tested it in their repeat-mutation
cellular model of the disease and found that it
could block toxic protein-production. Now, they
are screening for other molecules that might be
even more effective at blocking the process. 
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